RUSCONI, STEFANO
RUSCONI, STEFANO
Dipartimento di Scienze Biomediche e Cliniche
Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial
2024 G. Moyle, L. Assoumou, N. de Castro, F.A. Post, A. Curran, S. Rusconi, S. De Wit, C. Stephan, F. Raffi, M. Johnson, M. Masia, J. Vera, B. Jones, R. Grove, C. Fletcher, A. Duffy, K. Morris, A. Pozniak
A cautionary note on entry and exit strategies with long-acting cabotegravir and rilpivirine
2024 D. Ripamonti, S. Rusconi, M. Zazzi
Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors
2024 T. Clemente, L. Galli, R. Lolatto, R. Gagliardini, F. Lagi, M. Ferrara, A.M. Cattelan, E. Focà, A. Di Biagio, A. Cervo, L. Calza, F. Maggiolo, G. Marchetti, G. Cenderello, S. Rusconi, M. Zazzi, M.M. Santoro, V. Spagnuolo, A. Castagna
Heavily Treatment-Experienced Persons Living with HIV Currently in Care in Italy: characteristics, Risk Factors, and Therapeutic Options - the ICONA Foundation Cohort study
2024 S.L. Caputo, M. Poliseno, A. Tavelli, R. Gagliardini, S. Rusconi, G. Lapadula, A. Antinori, D. Francisci, L. Sarmati, A. Gori, V. Spagnuolo, F. Ceccherini-Silberstein, A.D. Monforte, A. Cozzi-Lepri
Pillars of long-term antiretroviral therapy success
2023 L. Taramasso, M. Andreoni, A. Antinori, A. Bandera, P. Bonfanti, S. Bonora, M. Borderi, A. Castagna, A.M. Cattelan, B.M. Celesia, S. Cicalini, A. Cingolani, A. Cossarizza, A. D'Arminio Monforte, G. D'Ettorre, A. Di Biagio, S. Di Giambenedetto, G. Di Perri, V. Esposito, E. Focà, C. Gervasoni, A. Gori, N. Gianotti, G. Guaraldi, R. Gulminetti, S. Lo Caputo, G. Madeddu, P. Maggi, G. Marandola, G.C. Marchetti, C.M. Mastroianni, C. Mussini, C.F. Perno, G. Rizzardini, S. Rusconi, M. Santoro, L. Sarmati, M. Zazzi, F. Maggiolo
Characterization and outcomes of difficult-to-treat patients starting modern first-line ART regimens: data from the ICONA cohort
2023 R. Gagliardini, A. Tavelli, S. Rusconi, S. Lo Caputo, V. Spagnuolo, M. Mercedes Santoro, A. Costantini, A. Vergori, F. Maggiolo, A. Giacomelli, G. Burastero, G. Madeddu, E. Quiros Roldan, A. D'ARMINIO MONFORTE, A. Antinori, A. Cozzi-Lepri
Primary HIV infection features colonic damage and neutrophil inflammation yet containment of microbial translocation
2023 C. Tincati, V. Bono, E.S. Cannizzo, D. Tosi, F. Savi, C. Falcinella, A. Casabianca, C. Orlandi, C. Luigiano, M. Augello, S. Rusconi, A. Muscatello, A. Bandera, A. Calcagno, A. Gori, S. Nozza, G. Marchetti
Effectiveness and safety of darunavir/cobicistat/emtricitabine/tenofovir alafenamide therapy in an observational Italian cohort: the DIAMANTE study
2023 A. Antinori, A. Vergori, D. Ripamonti, D. Valenti, G. Rizzardini, M. Vittoria Cossu, S. Rusconi, V. Esposito, A. Cascio, G. Orofino, M. Andreoni, E. Manzillo, A. Castagna, D. Mancusi, R. Termini, M. Portaro, A. Uglietti
HIV-DNA decrease during treatment in primary HIV-1 infection with three different drug regimens: Italian Network of Acute HIV Infection (INACTION) clinical trial
2023 E. Bruzzesi, A. Gabrieli, D. Bernasconi, G. Marchetti, A. Calcagno, D. Ripamonti, A. Antinori, N. Squillace, A. Cingolani, A. Muscatello, A. Bandera, A. Gori, S. Rusconi, S. Nozza
Investigating coping and stigma in people living with HIV through narrative medicine in the Italian multicentre non-interventional study DIAMANTE
2023 A. Antinori, A. Vergori, D. Ripamonti, D. Valenti, V. Esposito, M.A. Carleo, S. Rusconi, A. Cascio, E. Manzillo, M. Andreoni, G. Orofino, A. Cappuccio, L. Reale, M.G. Marini, D. Mancusi, R. Termini, A. Uglietti, M. Portaro
Sexually transmitted infections in people with multidrug-resistant HIV
2023 T. Clemente, R. Lolatto, R. Papaioannu Borjesson, M. Fabbiani, E. Manzillo, E. Fronti, S. Di Giambenedetto, R. Gagliardini, S. Rusconi, M.M. Santoro, A. Castagna, V. Spagnuolo
Long-term outcome of dolutegravir-containing regimens according to sex: data from the ICONA Study
2023 A. D'ARMINIO MONFORTE, M. Puoti, A. Tavelli, A. Saracino, S. Rusconi, S. Antinori, M. Sala, A. Mondi, B. MAURIZIO CELESIA, A. Cozzi-Lepri, L. Taramasso, A. Antinori
Invasive and Non-Invasive Human Salmonellosis Cases Admitted between 2015 and 2021 in Four Suburban Hospitals in the Metropolitan Area of Milan (Italy): A Multi-Center Retrospective Study
2023 G. Pagani, M. Parenti, M. Franzetti, L. Pezzati, F. Bassani, B. Osnaghi, L. Vismara, C. Pavia, P. Mirri, S. Rusconi
Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting
2023 P. Maggi, E.D. Ricci, C.V. Martinelli, G.V. De Socio, N. Squillace, C. Molteni, A. Masiello, G. Orofino, B. Menzaghi, R. Bellagamba, F. Vichi, B.M. Celesia, G. Madeddu, G.F. Pellicano, M.A. Carleo, A. Cascio, A. Parisini, L. Taramasso, L. Valsecchi, L. Calza, S. Rusconi, E. Sarchi, S. Martini, O. Bargiacchi, K. Falasca, G. Cenderello, S. Ferrara, A. Di Biagio, P. Bonfanti
Kinetics of CD169, HLA-DR, and CD64 expression as predictive biomarkers of SARS-CoV2 outcome
2023 A. Gatti, P. Fassini, A. Mazzone, S. Rusconi, B. Brando, G. Mistraletti
An update on long-acting agents in HIV therapy
2023 L. Pezzati, G. Canavesi, S. Rusconi
Incident diabetes in course of antiretroviral therapy
2023 L. Taramasso, N. Squillace, E. Ricci, B. Menzaghi, G. Orofino, G.V.D. Socio, C. Molteni, C.V. Martinelli, G. Madeddu, F. Vichi, L. Valsecchi, B.M. Celesia, P. Maggi, S. Rusconi, G.F. Pellicanò, A. Cascio, E. Sarchi, R. Gulminetti, K. Falasca, A. Di Biagio, P. Bonfanti
Efficacy of Dolutegravir versus Darunavir in Antiretroviral First-Line Regimens According to Resistance Mutations and Viral Subtype
2023 P. Francesco Salvo, D. Farinacci, A. Ciccullo, V. Borghi, S. Rusconi, A. Saracino, W. Gennari, B. Bruzzone, I. Vicenti, A. Callegaro, A. Di Biagio, M. Zazzi, S. Di Giambenedetto, A. Borghetti
Incidence of hypertension and blood pressure changes in persons with HIV at high risk for cardiovascular disease switching from boosted protease inhibitors to dolutegravir: a post-hoc analysis of the 96-week randomised NEAT-022 trial
2023 A. Sempere, L. Assoumou, A. González-Cordón, L. Waters, S. Rusconi, P. Domingo, M. Gompels, S. de Wit, F. Raffi, C. Stephan, M. Masiá, J. Rockstroh, C. Katlama, G.M.N. Behrens, G. Moyle, M. Johnson, J. Fox, H. Stellbrink, G. Guaraldi, E. Florence, S. Esser, J. Gatell, A. Pozniak, E. Martínez
Reduced probability of improving viro‐immunological state in subjects with vertical transmission of HIV reaching adult age: A multicenter retrospective cohort study
2023 F. Pennati, S. Calza, A. Di Biagio, C. Mussini, S. Rusconi, S. Bonora, A. Borghetti, E. Quiros‐roldan, G. Sarteschi, M. Menozzi, M. Ferrara, A. Celotti, A. Ciccullo, V. Giacomet, I. Izzo, L. Dotta, R. Badolato, F. Castelli, E. Focà